Dr Ioannis Papayannopoulos has been involved in mass spectrometry R&D for several decades, focusing primarily on proteins. He has held senior scientific and management roles in the biopharmaceutical industry and in academia, at such companies as Celldex Therapeutics, AstraZeneca, Biogen, and at the Koch Institute for Integrative Cancer Research at MIT, and he is currently Principal Scientist at Dragonfly Therapeutics, a biotechnology company in Massachusetts.

Dr Papayannopoulos received his PhD degree in Organic Chemistry from the Massachusetts Institute of Technology, under the supervision of the late Professor Klaus Biemann.